Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth

REFERENCES

• Adamson, P., C. J. Marshall, A. Hall, and P. A. Tilbrook. 1992. Post-translational modifications of p21rho proteins. J. Biol. Chem. 267:20033–20038.
   PubMed Web of Science ®Google Scholar
• Brymora, A., V. A. Valova, M. R. Larsen, B. D. Roufogalis, and P. J. Robinson. 2001. The brain exocyst complex interacts with RalA in a GTP-dependent manner: identification of a novel mammalian Sec3 gene and a second Sec15 gene. J. Biol. Chem. 276:29792–29797.
   PubMed Web of Science ®Google Scholar
• Casey, P. J., P. A. Solski, C. J. Der, and J. E. Buss. 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 86:8323–8327.
   PubMed Web of Science ®Google Scholar
• Chen, W. J., D. A. Andres, J. L. Goldstein, and M. S. Brown. 1991. Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA 88:11368–11372.
   PubMedGoogle Scholar
• Chen, W. J., D. A. Andres, J. L. Goldstein, D. W. Russell, and M. S. Brown. 1991. cDNA cloning and expression of the peptide-binding beta subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1. Cell 66:327–334.
   PubMedGoogle Scholar
• Chen, X. W., M. Inoue, S. C. Hsu, and A. R. Saltiel. 2006. RalA-exocyst-dependent recycling endosome trafficking is required for the completion of cytokinesis. J. Biol. Chem. 281:38609–38615.
   PubMedGoogle Scholar
• Chien, Y., S. Kim, R. Bumeister, Y. M. Loo, S. W. Kwon, C. L. Johnson, M. G. Balakireva, Y. Romeo, L. Kopelovich, M. Gale, Jr., C. Yeaman, J. H. Camonis, Y. Zhao, and M. A. White. 2006. RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127:157–170.
   PubMed Web of Science ®Google Scholar
• Chien, Y., and M. A. White. 2003. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep. 4:800–806.
   PubMed Web of Science ®Google Scholar
• Colicelli, J. 2004. Human RAS superfamily proteins and related GTPases. Sci. STKE 2004:RE13.
   PubMedGoogle Scholar
• Dan, H. C., K. Jiang, D. Coppola, A. Hamilton, S. V. Nicosia, S. M. Sebti, and J. Q. Cheng. 2004. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23:706–715.
   PubMed Web of Science ®Google Scholar
• Delarue, F. L., J. Adnane, B. Joshi, M. A. Blaskovich, D. A. Wang, J. Hawker, F. Bizouarn, J. Ohkanda, K. Zhu, A. D. Hamilton, S. Chellappan, and S. M. Sebti. 2007. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 26:633–640.
   PubMedGoogle Scholar
• Finegold, A. A., D. I. Johnson, C. C. Farnsworth, M. H. Gelb, S. R. Judd, J. A. Glomset, and F. Tamanoi. 1991. Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. Proc. Natl. Acad. Sci. USA 88:4448–4452.
   PubMedGoogle Scholar
• Fukai, S., H. T. Matern, J. R. Jagath, R. H. Scheller, and A. T. Brunger. 2003. Structural basis of the interaction between RalA and Sec5, a subunit of the sec6/8 complex. EMBO J. 22:3267–3278.
   PubMed Web of Science ®Google Scholar
• Garcia, A. M., C. Rowell, K. Ackermann, J. J. Kowalczyk, and M. D. Lewis. 1993. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 268:18415–18418.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Garcia, A., C. A. Pritchard, H. F. Paterson, G. Mavria, G. Stamp, and C. J. Marshall. 2005. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226.
   PubMed Web of Science ®Google Scholar
• Hamad, N. M., J. H. Elconin, A. E. Karnoub, W. Bai, J. N. Rich, R. T. Abraham, C. J. Der, and C. M. Counter. 2002. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2045–2057.
   PubMed Web of Science ®Google Scholar
• Henry, D. O., S. A. Moskalenko, K. J. Kaur, M. Fu, R. G. Pestell, J. H. Camonis, and M. A. White. 2000. Ral GTPases contribute to regulation of cyclin D1 through activation of NF-κB. Mol. Cell. Biol. 20:8084–8092.
   PubMed Web of Science ®Google Scholar
• Hinoi, T., S. Kishida, S. Koyama, M. Ikeda, Y. Matsuura, and A. Kikuchi. 1996. Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator. J. Biol. Chem. 271:19710–19716.
   PubMedGoogle Scholar
• Iurlaro, M., F. Demontis, M. Corada, L. Zanetta, C. Drake, M. Gariboldi, S. Peiro, A. Cano, P. Navarro, A. Cattelino, S. Tognin, P. C. Marchisio, and E. Dejana. 2004. VE-cadherin expression and clustering maintain low levels of survivin in endothelial cells. Am. J. Pathol. 165:181–189.
   PubMedGoogle Scholar
• Jackson, J. H., C. G. Cochrane, J. R. Bourne, P. A. Solski, J. E. Buss, and C. J. Der. 1990. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA 87:3042–3046.
   PubMed Web of Science ®Google Scholar
• Jin, R., J. R. Junutula, H. T. Matern, K. E. Ervin, R. H. Scheller, and A. T. Brunger. 2005. Exo84 and Sec5 are competitive regulatory Sec6/8 effectors to the RalA GTPase. EMBO J. 24:2064–2074.
   PubMed Web of Science ®Google Scholar
• Joyce, P. L., and A. D. Cox. 2003. Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. Cancer Res. 63:7959–7967.
   PubMedGoogle Scholar
• Kato, K., A. D. Cox, M. M. Hisaka, S. M. Graham, J. E. Buss, and C. J. Der. 1992. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89:6403–6407.
   PubMed Web of Science ®Google Scholar
• Kinsella, B. T., R. A. Erdman, and W. A. Maltese. 1991. Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J. Biol. Chem. 266:9786–9794.
   PubMedGoogle Scholar
• Lebowitz, P. F., W. Du, and G. C. Prendergast. 1997. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J. Biol. Chem. 272:16093–16095.
   PubMed Web of Science ®Google Scholar
• Leftheris, K., T. Kline, G. D. Vite, Y. H. Cho, R. S. Bhide, D. V. Patel, M. M. Patel, R. J. Schmidt, H. N. Weller, M. L. Andahazy, J. M. Carboni, J. L. Gullo-Brown, F. Y. Lee, C. Ricca, W. C. Rose, N. Yan, M. Barbacid, J. T. Hunt, C. A. Meyers, B. R. Seizinger, R. Zahler, and V. Manne. 1996. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem. 39:224–236.
   PubMed Web of Science ®Google Scholar
• Lim, K. H., A. T. Baines, J. J. Fiordalisi, M. Shipitsin, L. A. Feig, A. D. Cox, C. J. Der, and C. M. Counter. 2005. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7:533–545.
   PubMed Web of Science ®Google Scholar
• Lim, K. H., K. O'Hayer, S. J. Adam, S. D. Kendall, P. M. Campbell, C. J. Der, and C. M. Counter. 2006. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 16:2385–2394.
   PubMed Web of Science ®Google Scholar
• Manne, V., D. Roberts, A. Tobin, E. O'Rourke, M. De Virgilio, C. Meyers, N. Ahmed, B. Kurz, M. Resh, H. F. Kung, et al. 1990. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. USA 87:7541–7545.
   PubMed Web of Science ®Google Scholar
• Miquel, K., A. Pradines, J. Sun, Y. Qian, A. D. Hamilton, S. M. Sebti, and G. Favre. 1997. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 57:1846–1850.
   PubMed Web of Science ®Google Scholar
• Ohta, Y., N. Suzuki, S. Nakamura, J. H. Hartwig, and T. P. Stossel. 1999. The small GTPase RalA targets filamin to induce filopodia. Proc. Natl. Acad. Sci. USA 96:2122–2128.
   PubMed Web of Science ®Google Scholar
• Oxford, G., C. R. Owens, B. J. Titus, T. L. Foreman, M. C. Herlevsen, S. C. Smith, and D. Theodorescu. 2005. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res. 65:7111–7120.
   PubMedGoogle Scholar
• Peng, H., D. Carrico, V. Thai, M. Blaskovich, C. Bucher, E. E. Pusateri, S. M. Sebti, and A. D. Hamilton. 2006. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Org. Biomol. Chem. 4:1768–1784.
   PubMedGoogle Scholar
• Prendergast, G. C. 2001. Actin' up: RhoB in cancer and apoptosis. Nat. Rev. Cancer 1:162–168.
   PubMed Web of Science ®Google Scholar
• Qian, Y., A. Vogt, A. Vasudevan, S. M. Sebti, and A. D. Hamilton. 1998. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg. Med. Chem. 6:293–299.
   PubMed Web of Science ®Google Scholar
• Rangarajan, A., S. J. Hong, A. Gifford, and R. A. Weinberg. 2004. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6:171–183.
   PubMed Web of Science ®Google Scholar
• Reiss, Y., S. J. Stradley, L. M. Gierasch, M. S. Brown, and J. L. Goldstein. 1991. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA 88:732–736.
   PubMed Web of Science ®Google Scholar
• Repasky, G. A., E. J. Chenette, and C. J. Der. 2004. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14:639–647.
   PubMed Web of Science ®Google Scholar
• Rosse, C., A. Hatzoglou, M. C. Parrini, M. A. White, P. Chavrier, and J. Camonis. 2006. RalB mobilizes the exocyst to drive cell migration. Mol. Cell. Biol. 26:727–734.
   PubMed Web of Science ®Google Scholar
• Rowell, C. A., J. J. Kowalczyk, M. D. Lewis, and A. M. Garcia. 1997. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272:14093–14097.
   PubMed Web of Science ®Google Scholar
• Sahai, E., and C. J. Marshall. 2002. RHO-GTPases and cancer. Nat. Rev. Cancer 2:133–142.
   PubMed Web of Science ®Google Scholar
• Schafer, W. R., C. E. Trueblood, C. C. Yang, M. P. Mayer, S. Rosenberg, C. D. Poulter, S. H. Kim, and J. Rine. 1990. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science 249:1133–1139.
   PubMed Web of Science ®Google Scholar
• Seabra, M. C., Y. Reiss, P. J. Casey, M. S. Brown, and J. L. Goldstein. 1991. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 65:429–434.
   PubMed Web of Science ®Google Scholar
• Sebti, S. M., and C. J. Der. 2003. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat. Rev. Cancer 3:945–951.
   PubMed Web of Science ®Google Scholar
• Shipitsin, M., and L. A. Feig. 2004. RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells. Mol. Cell. Biol. 24:5746–5756.
   PubMed Web of Science ®Google Scholar
• St. Croix, B., C. Sheehan, J. W. Rak, V. A. Florenes, J. M. Slingerland, and R. S. Kerbel. 1998. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1. J. Cell Biol. 142:557–571.
   PubMed Web of Science ®Google Scholar
• Sugihara, K., S. Asano, K. Tanaka, A. Iwamatsu, K. Okawa, and Y. Ohta. 2002. The exocyst complex binds the small GTPase RalA to mediate filopodia formation. Nat. Cell Biol. 4:73–78.
   PubMed Web of Science ®Google Scholar
• Sun, J., M. A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, R. D. Bailey, A. D. Hamilton, and S. M. Sebti. 1999. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 59:4919–4926.
   PubMed Web of Science ®Google Scholar
• Sun, J., J. Ohkanda, D. Coppola, H. Yin, M. Kothare, B. Busciglio, A. D. Hamilton, and S. M. Sebti. 2003. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res. 63:8922–8929.
   PubMed Web of Science ®Google Scholar
• Sun, J., Y. Qian, Z. Chen, J. Marfurt, A. D. Hamilton, and S. M. Sebti. 1999. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem. 274:6930–6934.
   PubMedGoogle Scholar
• Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. 1998. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467–1473.
   PubMed Web of Science ®Google Scholar
• Vogt, A., J. Sun, Y. Qian, A. D. Hamilton, and S. M. Sebti. 1997. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21WAF1/CIP1/SDI1 in a p53-independent manner. J. Biol. Chem. 272:27224–27229.
   PubMed Web of Science ®Google Scholar
• Wennerberg, K., K. L. Rossman, and C. J. Der. 2005. The Ras superfamily at a glance. J. Cell Sci. 118:843–846.
   PubMed Web of Science ®Google Scholar
• Whyte, D. B., P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. Bishop, and J. K. Pai. 1997. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:14459–14464.
   PubMed Web of Science ®Google Scholar
• Yoshida, Y., M. Kawata, M. Katayama, H. Horiuchi, Y. Kita, and Y. Takai. 1991. A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase for ras p21S. Biochem. Biophys. Res. Commun. 175:720–728.
   PubMed Web of Science ®Google Scholar
• Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241–269.
   PubMed Web of Science ®Google Scholar
• Zhu, K., A. D. Hamilton, and S. M. Sebti. 2003. Farnesyltransferase inhibitors as anticancer agents: current status. Curr. Opin. Investig. Drugs 4:1428–1435.
   PubMedGoogle Scholar